Stage IV Pancreatic Cancer
Information
- Disease name
- Stage IV Pancreatic Cancer
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02166255 | Completed | Phase 1 | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | December 2014 | May 2016 |
| NCT00004074 | Completed | Phase 1 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | August 1999 | |
| NCT00028496 | Completed | Phase 1 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | November 2001 | |
| NCT00028834 | Completed | Phase 2 | Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer | February 2002 | |
| NCT00030498 | Completed | Phase 1 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | December 2001 | |
| NCT00031681 | Completed | Phase 1 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | December 2001 | |
| NCT00031694 | Completed | Phase 2 | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer | March 2002 | April 2010 |
| NCT00039403 | Completed | Phase 1 | UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer | April 2002 | |
| NCT00047307 | Completed | Phase 1 | Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer | August 2002 | |
| NCT00052689 | Completed | Phase 2 | Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer | December 2002 | |
| NCT00075647 | Completed | Phase 2 | CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | December 2003 | |
| NCT00085371 | Completed | Phase 2 | Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas | July 2004 | |
| NCT01643499 | Completed | Phase 1 | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | March 26, 2012 | July 2019 |
| NCT01647828 | Completed | Phase 1/Phase 2 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer | October 2012 | April 2016 |
| NCT01658943 | Completed | Phase 2 | Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy | August 2012 | June 2015 |
| NCT01666730 | Completed | Phase 2 | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | February 21, 2013 | August 1, 2018 |
| NCT01806675 | Completed | Phase 1/Phase 2 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | March 4, 2013 | April 2019 |
| NCT01835041 | Completed | Phase 1 | CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer | April 2013 | March 16, 2023 |
| NCT01839981 | Completed | Phase 1 | CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | July 2013 | October 2015 |
| NCT01846520 | Completed | N/A | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers | October 2013 | May 23, 2019 |
| NCT01893294 | Completed | Phase 1 | Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer | April 2013 | October 30, 2015 |
| NCT01893801 | Completed | Phase 1/Phase 2 | Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA | May 2013 | October 1, 2017 |
| NCT01924260 | Completed | Phase 1 | Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer | August 9, 2013 | February 8, 2017 |
| NCT02005315 | Completed | Phase 1 | A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | September 2013 | November 2017 |
| NCT02050178 | Completed | Phase 1 | Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer | November 2013 | June 15, 2017 |
| NCT02178436 | Completed | Phase 1/Phase 2 | Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | October 31, 2014 | April 5, 2023 |
| NCT02227940 | Completed | Phase 1 | Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | January 8, 2015 | February 12, 2019 |
| NCT02307539 | Completed | N/A | Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer | November 2014 | May 2015 |
| NCT02333188 | Completed | Phase 1 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | December 2014 | December 2017 |
| NCT02620865 | Completed | Phase 1/Phase 2 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | December 2015 | June 21, 2021 |
| NCT02896907 | Completed | Early Phase 1 | Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | October 18, 2016 | March 2019 |
| NCT03087591 | Completed | Phase 1 | APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery | April 28, 2017 | December 8, 2020 |
| NCT03095781 | Completed | Phase 1 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | July 7, 2017 | June 10, 2021 |
| NCT03222258 | Completed | Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients | December 17, 2016 | April 30, 2020 | |
| NCT03412799 | Completed | Phase 1 | Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | June 4, 2018 | February 28, 2022 |
| NCT00088894 | Completed | Phase 3 | Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | June 2004 | |
| NCT00091026 | Completed | Phase 2 | Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer | July 2004 | January 2011 |
| NCT00095966 | Completed | Phase 2 | Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | September 2004 | |
| NCT00101348 | Completed | Phase 1/Phase 2 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | January 2005 | May 2008 |
| NCT00114244 | Completed | Phase 2 | Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer | December 2004 | September 2010 |
| NCT00331682 | Completed | Phase 2 | Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer | March 2006 | May 2008 |
| NCT00383760 | Completed | Phase 2 | Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients | August 2006 | July 2011 |
| NCT00397384 | Completed | Phase 1 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | January 2007 | June 2013 |
| NCT00397787 | Completed | Phase 2 | Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine | November 2006 | |
| NCT00462553 | Completed | Phase 1 | Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors | March 2007 | |
| NCT00474812 | Completed | Phase 2 | Dasatinib in Treating Patients With Metastatic Pancreatic Cancer | May 2007 | February 2014 |
| NCT00577889 | Completed | Phase 2 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | March 2008 | May 2013 |
| NCT00617708 | Completed | Phase 1/Phase 2 | S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery | March 2008 | February 25, 2014 |
| NCT00735917 | Completed | Phase 2 | Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | October 2008 | October 2012 |
| NCT00981162 | Completed | Phase 1 | Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride | August 2009 | December 2012 |
| NCT01064622 | Completed | Phase 1/Phase 2 | Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | September 2009 | January 2013 |
| NCT01131234 | Completed | Phase 1 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | May 2010 | September 2014 |
| NCT01145456 | Completed | Phase 1 | Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors | June 2010 | |
| NCT01191684 | Completed | Phase 1 | Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer | October 2011 | August 2013 |
| NCT01195415 | Completed | Phase 2 | Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer | June 2010 | October 10, 2014 |
| NCT01222689 | Completed | Phase 2 | Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | November 2010 | September 2014 |
| NCT01232829 | Completed | Phase 2 | Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer | October 2010 | May 2014 |
| NCT01280058 | Completed | Phase 2 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | December 2010 | January 20, 2016 |
| NCT01453153 | Completed | Phase 1/Phase 2 | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | September 2011 | May 2015 |
| NCT01473940 | Completed | Phase 1 | Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | June 11, 2012 | May 6, 2018 |
| NCT01486329 | Completed | Phase 1 | VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer | December 2011 | December 2014 |
| NCT01488552 | Completed | Phase 1/Phase 2 | Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer | November 2011 | August 2016 |
| NCT01497392 | Completed | Phase 1 | Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers | March 29, 2012 | February 7, 2017 |
| NCT01525082 | Completed | Phase 2 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | December 2012 | December 31, 2019 |
| NCT01534637 | Completed | Phase 2 | Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer | August 2006 | August 2012 |
| NCT01537107 | Completed | Phase 1 | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | March 5, 2012 | June 27, 2018 |
| NCT05240690 | Not yet recruiting | Phase 1 | Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies | February 7, 2022 | December 31, 2024 |
| NCT05631574 | Recruiting | Phase 1 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | January 12, 2023 | October 2026 |
| NCT03682289 | Recruiting | Phase 2 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | January 17, 2019 | July 31, 2025 |
| NCT03368963 | Recruiting | Phase 1/Phase 2 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | January 30, 2018 | November 28, 2025 |
| NCT03825289 | Recruiting | Phase 1 | Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer | January 18, 2019 | January 18, 2026 |
| NCT05088889 | Recruiting | Phase 1 | Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer | January 25, 2022 | July 1, 2024 |
| NCT01282333 | Terminated | Phase 1 | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer | January 2011 | |
| NCT00003531 | Terminated | Phase 2 | Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer | April 10, 1996 | July 18, 2005 |
| NCT01555489 | Terminated | Phase 2 | Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | October 2011 | January 2016 |
| NCT00087191 | Terminated | N/A | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer | May 2004 | |
| NCT01851174 | Terminated | Phase 2 | Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer | February 2013 | January 2015 |
| NCT00416793 | Terminated | Phase 2 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | December 2006 | December 2009 |
| NCT02495896 | Terminated | Phase 1 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | September 3, 2015 | May 29, 2019 |
| NCT01227018 | Terminated | Phase 2 | PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer | December 2010 | May 2013 |
| NCT01233505 | Terminated | Phase 1 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | October 2010 | |
| NCT04267575 | Unknown status | N/A | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites | July 30, 2019 | April 14, 2023 |
| NCT04377048 | Unknown status | Phase 2 | Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer | July 1, 2020 | December 31, 2022 |
| NCT03154190 | Unknown status | N/A | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | August 8, 2017 | August 30, 2022 |
| NCT02414100 | Withdrawn | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy | December 12, 2013 | December 15, 2016 | |
| NCT02575508 | Withdrawn | Phase 1/Phase 2 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | ||
| NCT01927393 | Withdrawn | N/A | Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer | December 2014 | |
| NCT02048943 | Withdrawn | Phase 1 | Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer | March 2015 | |
| NCT01741597 | Withdrawn | Phase 1 | Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung | July 2014 |